Statins Associated with Decreased Risk of New Onset Inflammatory Bowel Disease

American Journal of Gastroenterology

Volumn 111, Issue 10, 2016, Pages 1416-1423

  Ungaro, Ryan ^a   Chang, Helena L ^a   Cote Daigneaut, Justin ^a   Mehandru, Saurabh ^a   Atreja, Ashish ^a   Colombel, Jean Frederic ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROHN DISEASE; DRUG EXPOSURE; FEMALE; HORMONE SUBSTITUTION; HUMAN; ICD-9; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; AGE; AGED; INCIDENCE; MIDDLE AGED; ODDS RATIO; PROTECTION; STATISTICAL MODEL; UNITED STATES;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROTECTIVE FACTORS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84990882935     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.233     Document Type: Article

References (53)

1. Orholm M, Binder V, Sørensen TI et al. Concordance of infl ammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000; 35: 1075-81.
2. Halfvarson J, Bodin L, Tysk C et al. Infl ammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003; 124: 1767-73.
3. Cosnes J, Gower-Rousseau C, Seksik P et al. Epidemiology and natural history of infl ammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
4. Joossens M, Simoens M, Vermeire S et al. Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases. Infl amm Bowel Dis 2007; 13: 580-4.
5. Andersson RE, Olaison G, Tysk C et al. Appendectomy and protection against ulcerative colitis. N Engl J Med 2001; 344: 808-14.
6. Andersson RE, Olaison G, Tysk C et al. Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 2003; 124: 40-6.
7. Mahid SS, Minor KS, Soto RE et al. Smoking and infl ammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462-71.
8. Ananthakrishnan AN, Khalili H, Higuchi LM et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 2012; 142: 482-9.
9. Ananthakrishnan AN, Khalili H, Konijeti GG et al. A prospective study of long-term intake of dietary fi ber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013; 145: 970-7.
10. De Vroey B, De Cassan C, Gower-Rousseau C et al. Editorial: antibiotics earlier, IBD later? Am J Gastroenterol 2010; 105: 2693-6.
11. Ungaro R, Bernstein CN, Gearry R et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 2014; 109: 1728-38.
12. Cornish JA, Tan E, Simillis C et al. The risk of oral contraceptives in the etiology of infl ammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008; 103: 2394-400.
13. Khalili H, Higuchi LM, Ananthakrishnan AN et al. Hormone therapy increases risk of ulcerative colitis but not crohn's disease. Gastroenterology 2012; 143: 1199-206.
14. Crockett SD, Porter CQ, Martin CF et al. Isotretinoin use and the risk of infl ammatory bowel disease: a case-control study. Am J Gastroenterol 2010; 105: 1986-93.
15. Etminan M, Bird ST, Delaney JA et al. Isotretinoin and risk for infl ammatory bowel disease: A nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013; 149: 216-20.
16. Chan SS, Luben R, Bergmann MM et al. Aspirin in the aetiology of crohn's disease and ulcerative colitis: A european prospective cohort study. Aliment Pharmacol Ther 2011; 34: 649-55.
17. Ananthakrishnan AN, Higuchi LM, Huang ES et al. Aspirin, nonsteroidal anti-infl ammatory drug use, and risk for crohn disease and ulcerative colitis: A cohort study. Ann Intern Med 2012; 156: 350-9.
18. Evans JM, McMahon AD, Murray FE et al. Non-steroidal anti-infl ammatory drugs are associated wiThemergency admission to hospital for colitis due to infl ammatory bowel disease. Gut 1997; 40: 619-22.
19. Gleeson MH, Davis AJ. Non-steroidal anti-infl ammatory drugs, aspirin and newly diagnosed colitis: a case-control study. Aliment Pharmacol Ther 2003; 17: 817-25.
20. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular Effects associated with statins. BMJ 2014; 349: g3743.
21. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
22. Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res 2013; 56: 348-57.
23. Crockett SD, Hansen R, Stürmer T et al. Statins are associated with reduced use of steroids in infl ammatory bowel disease: a retrospective cohort study. Infl amm Bowel Dis 2012; 18: 1048-56.
24. Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an antiinfl ammatory treatment in Crohn's disease. Br J Pharmacol 2008; 155: 1085-92.
25. Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One 2009; 4: 1-6.
26. Higgins PD, Khan T, Mapili J et al. Atorvastatin decreases Seo Index in patients with short duration of disease in ulcerative colitis: A randomized placebo-controlled clinical\trial. Gastroenterology 2006; 130: A120.
27. vanDeen WK, van Oijen MGH, Myers KD et al. A nationwide 2010-2012 analysis of U. S. health care utilization in infl ammatory bowel diseases. Infl amm Bowel Dis 2014; 20: 1747-53.
28. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of crohn's disease and ulcerative colitis. Am J Gastroenterol 2011; 106: 2133-42.
29. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012; 35: 2665-73.
30. Targownik LE, Suissa S. Understanding and avoiding immortal-time bias in gastrointestinal observational research. Am J Gastroenterol 2015; 110: 1647-50.
31. Kronman MP, Zaoutis TE, Haynes K et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012; 130: e794-803.
32. Virta L, Auvinen A, Helenius H et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease-a nationwide, register-based Finnish case-control study. Am J Epidemiol 2012; 175: 775-84.
33. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-934.
34. García Rodríguez LA, González-Pérez A, Johansson S et al. Risk factors for infl ammatory bowel disease in the general population. Aliment Pharmacol Ther 2005; 22: 309-15.
35. Khalili H, Higuchi LM, Ananthakrishnan AN et al. Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. Gastroenterology 2012; 143: 1199-206.
36. Khalili H, Higuchi LM, Ananthakrishnan AN et al. Oral contraceptives, reproductive factors and risk of infl ammatory bowel disease. Gut 2013; 62: 1153-9.
37. Khalil D, Boktor M, Mortensen EM et al. Comparison of frequency of infl ammatory bowel disease and noninfectious gastroenteritis among statin users versus nonusers. Am J Cardiol 2015; 115: 1396-401.
38. Ulivieri C, Baldari CT. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th 17-mediated autoimmune diseases. Pharacol Res 2014; 88: 41-52.
39. Lv S, Liu Y, Zou Z et al. The impact of statins therapy on disease activity and infl ammatory factor in patients with rheumatoid arthritis: a metaanalysis. Clin Exp Rheumatol 2015; 33: 69-76.
40. Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsingremitting multiple sclerosis. The Lancet 2004; 363: 1607-8.
41. Fatemi A, Moosavi M, Sayedbonakdar Z et al. Atorvastatin Effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial. Clin Rheumatol 2014; 33: 1273-8.
42. Bereswill S, Muñoz M, Fischer A et al. Anti-infl ammatory Effects of Resveratrol, Curcumin and Simvastatin in acute small intestinal infl ammation. PLoS One 2010; 5: e15099.
43. Youssef S, Stüve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th 2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
44. Jahovic N, Gedik N, Ercan F et al. Effects of statins on experimental colitis in normocholesterolemic rats. Scand J Gastroenterol 2006; 41: 954-62.
45. Aktunc E, Kayhan B, Arasli M et al. The Effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis. Immunopharmacol Immunotoxicol 2011; 33: 667-75.
46. Sasaki M, Bharwani S, Jordan P et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and infl ammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther 2003; 305: 78-85.
47. Antonopoulos S, Margaritis M, Lee R et al. Statins as anti-infl ammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18: 1519-30.
48. Ibrahim CB, Aroniadis OC, Brandt LJ. On the role of ischemia in the pathogenesis of IBD. A review. Infl amm Bowel Dis 2010; 16: 696-702.
49. Ruel J, Ruane D, Mehandru S et al. IBD across the age spectrum: is it the same disease? Nat Rev Gastroenterol Hepatol 2014; 11: 88-98.
50. Ikeda M, Takeshima F, Isomoto H et al. Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis. D ig Dis Sci 2 008; 5 3: 1 869-7 5.
51. Crohn's and Colitis Foundation of America. The Facts About Infl ammatory Bowel Disease, 2014. Accessed at http://www. ccfa. org/assets/pdfs/updatedibdfactbook. pdf.
52. United States Department of Labor. Fact Sheet: Young Adults and the Aff ordable Care Act: Protecting Young Adults and Eliminating Burdens on Families and Businesses. Accessed at https://www. dol. gov/ebsa/newsroom/ fsdependentcoverage. html.
53. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998; 54: 948-63.